Agios Q4 net loss $95.9M; positive mitapivat Phase 3 for NTD thalassemia

AGIOS PHARMACEUTICALS, INC.

2023-FY EPS reported -$6.33 revenue$26,823,000

Q4 PYRUKYND US net revenue $7.1M (down 4% QoQ); full year 2023 $26.8M.
Net loss $95.9M in Q4 vs net income $36.5M in Q4 2022; full year loss $352.1M.
Positive Phase 3 ENERGIZE study in non-transfusion-dependent thalassemia met primary endpoint.
Cash & equivalents $806.4M; company expects runway into 2026.
Pipeline milestones: ENERGIZE-T data mid-2024; FDA filing for mitapivat in thalassemia end-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

AGIOS PHARMACEUTICALS, INC. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 15, 2024, Agios Pharmaceuticals, Inc. issued a press release announcing its results for the quarter and year ended December 31, 2023 and other business highlights.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

AGIOS PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001439222-24-000032

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.